These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 19807206)

  • 1. De-risking drug discovery with ADDME -- avoiding drug development mistakes early.
    Tsaioun K; Jacewicz M
    Altern Lab Anim; 2009 Sep; 37 Suppl 1():47-55. PubMed ID: 19807206
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ADDME--Avoiding Drug Development Mistakes Early: central nervous system drug discovery perspective.
    Tsaioun K; Bottlaender M; Mabondzo A;
    BMC Neurol; 2009 Jun; 9 Suppl 1(Suppl 1):S1. PubMed ID: 19534730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preclinical pharmacokinetics: an approach towards safer and efficacious drugs.
    Singh SS
    Curr Drug Metab; 2006 Feb; 7(2):165-82. PubMed ID: 16472106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Informing the Selection of Screening Hit Series with in Silico Absorption, Distribution, Metabolism, Excretion, and Toxicity Profiles.
    Sanders JM; Beshore DC; Culberson JC; Fells JI; Imbriglio JE; Gunaydin H; Haidle AM; Labroli M; Mattioni BE; Sciammetta N; Shipe WD; Sheridan RP; Suen LM; Verras A; Walji A; Joshi EM; Bueters T
    J Med Chem; 2017 Aug; 60(16):6771-6780. PubMed ID: 28418656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in physicochemical and ADMET profiling in drug discovery.
    Wang J; Skolnik S
    Chem Biodivers; 2009 Nov; 6(11):1887-99. PubMed ID: 19937823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In silico ADME-Tox modeling: progress and prospects.
    Alqahtani S
    Expert Opin Drug Metab Toxicol; 2017 Nov; 13(11):1147-1158. PubMed ID: 28988506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The importance of HT-ADME in drug discovery.
    Morgan D
    Bioanalysis; 2011 Nov; 3(21):2385-7. PubMed ID: 22074279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comprehensive assessment of ADMET risks in drug discovery.
    Wang J
    Curr Pharm Des; 2009; 15(19):2195-219. PubMed ID: 19601823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of drug transporter interactions in drug discovery and development.
    Lai Y; Sampson KE; Stevens JC
    Comb Chem High Throughput Screen; 2010 Feb; 13(2):112-34. PubMed ID: 20053160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exploiting pluripotent stem cell technology for drug discovery, screening, safety, and toxicology assessments.
    McGivern JV; Ebert AD
    Adv Drug Deliv Rev; 2014 Apr; 69-70():170-8. PubMed ID: 24309014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Requirements for a lead compound to become a clinical candidate.
    Hefti FF
    BMC Neurosci; 2008 Dec; 9 Suppl 3(Suppl 3):S7. PubMed ID: 19091004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug discovery through stem cell-based organoid models.
    Ranga A; Gjorevski N; Lutolf MP
    Adv Drug Deliv Rev; 2014 Apr; 69-70():19-28. PubMed ID: 24582599
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of absorption, distribution, metabolism, excretion and toxicity in drug discovery.
    Lin J; Sahakian DC; de Morais SM; Xu JJ; Polzer RJ; Winter SM
    Curr Top Med Chem; 2003; 3(10):1125-54. PubMed ID: 12769713
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Approaches for high-throughput pharmacokinetic screening of low-molecular-weight drug candidates.
    Fontana S
    Expert Opin Drug Metab Toxicol; 2014 Feb; 10(2):139-42. PubMed ID: 24329157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In silico prediction of cytochrome P450-mediated drug metabolism.
    Zhang T; Chen Q; Li L; Liu LA; Wei DQ
    Comb Chem High Throughput Screen; 2011 Jun; 14(5):388-95. PubMed ID: 21470181
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicology in the drug discovery and development process.
    Dorato MA; Buckley LA
    Curr Protoc Pharmacol; 2006 Apr; Chapter 10():Unit10.3. PubMed ID: 22294168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive QSAR modeling for the successful predictions of the ADMET properties of candidate drug molecules.
    Khan MT; Sylte I
    Curr Drug Discov Technol; 2007 Oct; 4(3):141-9. PubMed ID: 17985997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The new pre-preclinical paradigm: compound optimization in early and late phase drug discovery.
    Caldwell GW; Ritchie DM; Masucci JA; Hageman W; Yan Z
    Curr Top Med Chem; 2001 Nov; 1(5):353-66. PubMed ID: 11899102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolism profiling, and cytochrome P450 inhibition & induction in drug discovery.
    Yan Z; Caldwell GW
    Curr Top Med Chem; 2001 Nov; 1(5):403-25. PubMed ID: 11899105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling ADMET.
    Ghosh J; Lawless MS; Waldman M; Gombar V; Fraczkiewicz R
    Methods Mol Biol; 2016; 1425():63-83. PubMed ID: 27311462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.